CDK4/6 inhibitors (CDK4/6i) have shown impressive improvement of PFS and OS in ER+ advanced breast cancer in combination with either aromatase inhibitors or fulvestrant, and these combinations have recently become standard-of-care in this patient population18–23. Here, CYP19A1 is linked to breast cancer.